688302 海创药业
交易中 03-10 09:55:29
资讯
新帖
简况
每周股票复盘：海创药业（688302）MASH药物完成IIa期入组
证券之星 · 03-08 02:57
每周股票复盘：海创药业（688302）MASH药物完成IIa期入组
海创药业（688302）披露HP515 IIa期临床试验完成全部参与者入组，3月3日股价下跌5.06%
证券之星 · 03-03
海创药业（688302）披露HP515 IIa期临床试验完成全部参与者入组，3月3日股价下跌5.06%
海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床IIa期试验完成参与者入组
智通财经 · 03-03
海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床IIa期试验完成参与者入组
3月3日海创药业跌5.06%，鹏华医药科技股票A基金重仓该股
证券之星 · 03-03
3月3日海创药业跌5.06%，鹏华医药科技股票A基金重仓该股
股市必读：海创药业发布2025年度业绩快报，亏损1.367亿元
证券之星 · 03-02
股市必读：海创药业发布2025年度业绩快报，亏损1.367亿元
每周股票复盘：海创药业（688302）2025年净亏1.367亿同比减亏
证券之星 · 03-01
每周股票复盘：海创药业（688302）2025年净亏1.367亿同比减亏
马年首周857家公司披露业绩快报，4家净利增速超10倍
21世纪经济报道 · 02-28
马年首周857家公司披露业绩快报，4家净利增速超10倍
海创药业（688302）披露2025年度业绩快报，2月27日股价上涨0.43%
证券之星 · 02-27
海创药业（688302）披露2025年度业绩快报，2月27日股价上涨0.43%
每周股票复盘：海创药业（688302）获GMP认证生产扩容
证券之星 · 02-08
每周股票复盘：海创药业（688302）获GMP认证生产扩容
股市必读：海创药业（688302）预计2025年全年扣除后营业收入:1,900万元至2,200万元
证券之星 · 02-02
股市必读：海创药业（688302）预计2025年全年扣除后营业收入:1,900万元至2,200万元
每周股票复盘：海创药业（688302）募投项目延期至2026年底
证券之星 · 2025-12-28
每周股票复盘：海创药业（688302）募投项目延期至2026年底
储能行业点评报告：全球首款锂钠协同储能方案发布，AIDC配储增量可期
华龙证券 · 2025-12-22
储能行业点评报告：全球首款锂钠协同储能方案发布，AIDC配储增量可期
12月11日海创药业涨6.32%，鹏华医药科技股票A基金重仓该股
证券之星 · 2025-12-11
12月11日海创药业涨6.32%，鹏华医药科技股票A基金重仓该股
创新药概念局部活跃 海创药业涨超11%
每日经济新闻 · 2025-12-11
创新药概念局部活跃 海创药业涨超11%
海创药业（688302）披露拟变更公司住所及修订公司章程，12月8日股价下跌0.94%
证券之星 · 2025-12-08
海创药业（688302）披露拟变更公司住所及修订公司章程，12月8日股价下跌0.94%
海创药业(688302.SH)：氘恩扎鲁胺软胶囊被纳入2025年国家医保药品目录
智通财经 · 2025-12-07
海创药业(688302.SH)：氘恩扎鲁胺软胶囊被纳入2025年国家医保药品目录
海创药业(688302.SH)：口服PROTAC药物HP518片联合抗肿瘤药物治疗晚期前列腺癌获批临床试验
智通财经 · 2025-11-24
海创药业(688302.SH)：口服PROTAC药物HP518片联合抗肿瘤药物治疗晚期前列腺癌获批临床试验
每周股票复盘：海创药业（688302）将召开2025年第三季度业绩说明会
证券之星 · 2025-11-09
每周股票复盘：海创药业（688302）将召开2025年第三季度业绩说明会
海创药业（688302）披露召开2025年第三季度业绩说明会公告，11月06日股价下跌2.17%
证券之星 · 2025-11-06
海创药业（688302）披露召开2025年第三季度业绩说明会公告，11月06日股价下跌2.17%
海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床II期试验完成首批参与者入组
智通财经 · 2025-11-04
海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床II期试验完成首批参与者入组
加载更多
公司概况
公司名称：
海创药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-04-12
主营业务：
海创药业股份有限公司的主营业务是肿瘤、代谢性疾病等重大治疗领域的创新药物研发。公司的主要产品是HC-1119、HP518（PROTAC）、HP568（PROTAC）、HP537、HP560、HP501、HP515。公司荣获“2024年成都市企业技术中心”，“2024中国医药研发排行榜化药榜单前100强”，“成都市高新区“金熊猫未来星”·企业关键核心技术奖”等荣誉及称号。
发行价格：
42.92
{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业","latestPrice":43.22,"timestamp":1773107729000,"preClose":42.03,"halted":0,"volume":423520,"delay":0,"changeRate":0.0283,"floatShares":99015600,"shares":99015600,"eps":-1.4601,"marketStatus":"交易中","change":1.19,"latestTime":"03-10 09:55:29","open":42.05,"high":43.68,"low":42.05,"amount":18211800,"amplitude":0.0388,"askPrice":43.22,"askSize":2,"bidPrice":43.17,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-1.4601,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1773113400000},"marketStatusCode":2,"adr":0,"adjPreClose":42.03,"symbolType":"stock_kcb","openAndCloseTimeList":[[1773106200000,1773113400000],[1773118800000,1773126000000]],"highLimit":46.23,"lowLimit":37.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":99015598,"isCdr":false,"pbRate":3.78,"roa":"--","roe":"--","epsLYR":-2.01,"committee":-0.681818,"marketValue":4279000000,"turnoverRate":0.0043,"status":0,"floatMarketCap":4279000000},"requestUrl":"/m/hq/s/688302","defaultTab":"news","newsList":[{"id":"2617800663","title":"每周股票复盘：海创药业（688302）MASH药物完成IIa期入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2617800663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617800663?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:57","pubTimestamp":1772909828,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，海创药业报收于42.6元，较上周的44.19元下跌3.6%。本周，海创药业3月2日盘中最高价报44.1元。本周关注点公司公告汇总：HP515片治疗MASH的IIa期临床试验完成全部参与者入组。HP515为口服高选择性THR-β激动剂，已获中国和美国药品监管部门批准开展MASH适应症临床试验。截至目前，国内尚无同类靶点产品获批上市。该进展对公司近期业绩无重大影响，后续存在研发不确定性风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2616299423","title":"海创药业（688302）披露HP515 IIa期临床试验完成全部参与者入组，3月3日股价下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616299423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616299423?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:36","pubTimestamp":1772548580,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，海创药业报收于40.15元，较前一交易日下跌5.06%，最新总市值为39.75亿元。该股当日开盘42.47元，最高42.88元，最低40.0元，成交额达8007.17万元，换手率为1.97%。近日，海创药业股份有限公司自愿披露，其自主研发的治疗代谢相关脂肪性肝炎药物HP515的IIa期临床试验已顺利完成全部参与者入组。HP515为口服THR-β激动剂，前期I期试验显示其在安全性、药代动力学及药效学方面表现良好，SHBG呈剂量依赖性上升，血脂指标LDL-C、TC、ApoB显著下降。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300044567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2616344597","title":"海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床IIa期试验完成参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2616344597","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616344597?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:42","pubTimestamp":1772538125,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业(688302.SH)公告，公司自主研发的拟用于治疗代谢相关脂肪性肝炎(MASH，曾用名非酒精性脂肪性肝炎(NASH))的HP515临床IIa期试验于近日已完成全部参与者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2616317863","title":"3月3日海创药业跌5.06%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616317863","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616317863?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:36","pubTimestamp":1772527004,"startTime":"0","endTime":"0","summary":"证券之星消息，3月3日海创药业跌5.06%创60日新低，收盘报40.15元，换手率1.97%，成交量1.95万手，成交额8007.17万元。重仓海创药业的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为17.21亿元，最新净值1.6766，较上一交易日下跌1.9%，近一年上涨43.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300029022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","09939","BK1574","688302","BK0239","159938"],"gpt_icon":0},{"id":"2616140876","title":"股市必读：海创药业发布2025年度业绩快报，亏损1.367亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616140876","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616140876?lang=zh_cn&edition=full","pubTime":"2026-03-02 03:10","pubTimestamp":1772392224,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，海创药业报收于44.19元，上涨0.43%，换手率0.7%，成交量6971.0手，成交额3061.84万元。业绩披露要点业绩快报海创药业近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损1.367亿元，同比增长31.48%。业绩增长主要因首个1类新药氘恩扎鲁胺软胶囊于2025年5月获批上市并实现销售收入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2616456138","title":"每周股票复盘：海创药业（688302）2025年净亏1.367亿同比减亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2616456138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616456138?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:45","pubTimestamp":1772304313,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，海创药业报收于44.19元，较上周的45.1元下跌2.02%。本周，海创药业2月24日盘中最高价报45.63元。本周关注点来自业绩披露要点：海创药业2025年归属净利润亏损1.367亿元，同比减亏31.48%。公司公告汇总海创药业发布2025年度业绩快报，营业总收入2,067.38万元，同比增长5,535.71%；归属于母公司所有者的净利润为-13,668.75万元，同比减亏6,280.83万元。业绩增长主要因首个1类新药氘恩扎鲁胺软胶囊于2025年5月获批上市并实现销售收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2614468811","title":"马年首周857家公司披露业绩快报，4家净利增速超10倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2614468811","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614468811?lang=zh_cn&edition=full","pubTime":"2026-02-28 20:15","pubTimestamp":1772280900,"startTime":"0","endTime":"0","summary":" 马年首周，A股上市公司业绩迎来密集披露。 21快讯记者据同花顺iFind统计，截至2月28日，马年首周已有857家A股上市公司披露2025年业绩快报，470家归母净利润实现同比增长，其中电子、机械设备和医药生物行业占比位居前三，分别为97家、77家和69家，具备较强的业绩基本面支撑。业绩快报显示，海创药业2025年实现营业收入0.21亿元，同比激增5536.26%。然而，2025年公司归母净利润仍亏损1.37亿元，不过较去年同期已减亏31.48%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2026-02-28/doc-inhpkpem2997655.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-02-28/doc-inhpkpem2997655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0224","BK0214","SINA","BK0239","688223","688498","SGXZ49509284.SGD","688302","SGXZ81163826.USD"],"gpt_icon":0},{"id":"2614857037","title":"海创药业（688302）披露2025年度业绩快报，2月27日股价上涨0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614857037","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614857037?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:17","pubTimestamp":1772205430,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，海创药业报收于44.19元，较前一交易日上涨0.43%，最新总市值为43.75亿元。该股当日开盘43.53元，最高44.25元，最低43.49元，成交额达3061.84万元，换手率为0.7%。近日，海创药业披露2025年度业绩快报。业绩变动主要因首个1类新药氘恩扎鲁胺软胶囊于2025年5月获批上市并实现销售收入。截至2025年末，公司总资产为131,470.03万元，同比减少3.44%；归属于母公司的所有者权益为106,412.38万元，同比减少10.75%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2609185526","title":"每周股票复盘：海创药业（688302）获GMP认证生产扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2609185526","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609185526?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:00","pubTimestamp":1770490837,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，海创药业报收于45.83元，较上周的46.0元下跌0.37%。本周，海创药业2月6日盘中最高价报46.67元。本周关注点公司公告汇总：海创药业软胶囊剂生产线通过GMP符合性检查，生产范围新增抗肿瘤药。此次变更有助于公司优化生产结构，提升核心竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2608092881","title":"股市必读：海创药业（688302）预计2025年全年扣除后营业收入:1,900万元至2,200万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608092881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608092881?lang=zh_cn&edition=full","pubTime":"2026-02-02 05:06","pubTimestamp":1769979978,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，海创药业报收于46.0元，下跌0.28%，换手率1.24%，成交量1.23万手，成交额5671.17万元。业绩披露要点业绩预告海创药业发布业绩预告，预计2025年全年归属净利润亏损1.25亿元至1.5亿元；扣非后净利润亏损1.55亿元至1.85亿元；营业收入预计为1900万元至2200万元；扣除后营业收入为1900万元至2200万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302"],"gpt_icon":0},{"id":"2594424402","title":"每周股票复盘：海创药业（688302）募投项目延期至2026年底","url":"https://stock-news.laohu8.com/highlight/detail?id=2594424402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594424402?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:17","pubTimestamp":1766866628,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，海创药业报收于50.29元，较上周的52.44元下跌4.1%。本周，海创药业12月22日盘中最高价报53.15元。会议审议通过《关于审议豁免本次会议通知时限的议案》和《关于首次公开发行股票部分募投项目延期的议案》。董事会认为项目延期系基于实际情况的审慎决定，程序合规，未损害股东利益。“研发生产基地建设项目”原定于2025年12月31日达到预定可使用状态，现调整至2026年12月31日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2593482191","title":"储能行业点评报告：全球首款锂钠协同储能方案发布，AIDC配储增量可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2593482191","media":"华龙证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593482191?lang=zh_cn&edition=full","pubTime":"2025-12-22 20:07","pubTimestamp":1766405252,"startTime":"0","endTime":"0","summary":"全球首款锂钠协同储能方案发布。AIDC配储渗透率及配储时长有望提升，我们测算2030年AIDC配储需求或超100gwh。我们认为2026年储能市场或延续高速增长态势，AIDC配套储能系统有望迎来规模化部署高峰期，大储市场需求正向“4小时及更长时长”迁移。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222200743a6c167ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222200743a6c167ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["300750","LU1152091754.HKD","LU0880133367.SGD","03750","LU1807302812.USD","688599","LU1152091168.USD","LU1008478684.HKD","688302","LU1960683339.HKD","LU1993786604.SGD","300014","LU0067412154.USD","688472","002150","BK1116","300274","BK1610"],"gpt_icon":1},{"id":"2590560774","title":"12月11日海创药业涨6.32%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590560774","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590560774?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:33","pubTimestamp":1765438438,"startTime":"0","endTime":"0","summary":"证券之星消息，12月11日海创药业涨6.32%创60日新高，收盘报57.0元，换手率7.01%，成交量6.94万手，成交额3.96亿元。该股为创新药、医药概念热股。重仓海创药业的公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为19.21亿元，最新净值1.7336，较上一交易日上涨0.14%，近一年上涨57.61%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100019510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1515","688302","BK1574","BK0239","159938","09939"],"gpt_icon":0},{"id":"2590566181","title":"创新药概念局部活跃 海创药业涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590566181","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590566181?lang=zh_cn&edition=full","pubTime":"2025-12-11 11:09","pubTimestamp":1765422540,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月11日，创新药概念局部活跃，海创药业涨超11%，前沿生物涨超8%，重药控股此前涨停，悦康药业、热景生物、回盛生物、众生药业跟涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-11/doc-inhakwan8087335.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-11/doc-inhakwan8087335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","688302","BK0239","159992","BK1161","06978"],"gpt_icon":0},{"id":"2589393943","title":"海创药业（688302）披露拟变更公司住所及修订公司章程，12月8日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589393943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589393943?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:52","pubTimestamp":1765187571,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，海创药业报收于47.51元，较前一交易日下跌0.94%，最新总市值为47.04亿元。该股当日开盘49.45元，最高49.78元，最低47.45元，成交额达7010.09万元，换手率为1.46%。根据近日发布的公告，海创药业拟变更公司住所，由四川省成都市高新区科园南路5号蓉药大厦1栋4层附2、3号变更为四川省成都市双流区凤凰路558号。为配合上述事项，公司将相应修订《公司章程》第五条关于住所的条款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800022657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2589321879","title":"海创药业(688302.SH)：氘恩扎鲁胺软胶囊被纳入2025年国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589321879","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589321879?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:10","pubTimestamp":1765095050,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业(688302.SH)发布公告，2025年12月7日，国家医保局、人力资源社会保障部公布了《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(以下简称“国家医保药品目录”)，公司自主研发的氘恩扎鲁胺软胶囊通过国家医保谈判，首次被纳入国家医保药品目录，该目录将于2026年1月1日起执行。氘恩扎鲁胺软胶囊(曾用名：HC-1119软胶囊)是公司自主研发的、用于治疗转移性去势抵抗性前列腺癌(mCRPC)的1类新药，是第二代雄激素受体(AR)抑制剂，获得国家重大新药创制科技重大专项支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海创药业(688302.SH)：氘恩扎鲁胺软胶囊被纳入2025年国家医保药品目录","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2585126457","title":"海创药业(688302.SH)：口服PROTAC药物HP518片联合抗肿瘤药物治疗晚期前列腺癌获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2585126457","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585126457?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:10","pubTimestamp":1763975404,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业 发布公告，近日，公司收到中国国家药品监督管理局药品审评中心核准签发的《药物临床试验批准通知书》，同意HP518片联合抗肿瘤药物开展用于治疗晚期前列腺癌的Ⅰb/Ⅱ期临床试验。截至目前，HP518片已分别于中国、澳大利亚和美国三个国家获批开展用于晚期前列腺癌的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海创药业(688302.SH)：口服PROTAC药物HP518片联合抗肿瘤药物治疗晚期前列腺癌获批临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2582641198","title":"每周股票复盘：海创药业（688302）将召开2025年第三季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582641198","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582641198?lang=zh_cn&edition=full","pubTime":"2025-11-09 05:18","pubTimestamp":1762636699,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，海创药业报收于47.5元，较上周的52.25元下跌9.09%。本周，海创药业11月3日盘中最高价报52.79元。海创药业当前最新总市值47.03亿元，在化学制药板块市值排名111/151，在两市A股市值排名3508/5166。本周关注点公司公告汇总：海创药业将于2025年11月14日召开第三季度业绩说明会，介绍经营成果及财务状况。投资者可于2025年11月7日至11月13日16:00前通过上证路演中心网站或公司邮箱ir@hinovapharma.com提问，公司将在说明会上对普遍关注的问题进行回应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2581709121","title":"海创药业（688302）披露召开2025年第三季度业绩说明会公告，11月06日股价下跌2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709121","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581709121?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:23","pubTimestamp":1762439001,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，海创药业报收于47.72元，较前一交易日下跌2.17%，最新总市值为47.25亿元。该股当日开盘48.99元，最高49.12元，最低47.65元，成交额达6876.37万元，换手率为1.44%。近日，海创药业发布公告称，公司将于2025年11月14日14:00-15:00通过上证路演中心网络文字互动方式召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果及财务状况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2580200041","title":"海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床II期试验完成首批参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2580200041","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580200041?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:25","pubTimestamp":1762244730,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业 发布公告，公司自主研发的拟用于治疗代谢相关脂肪性肝炎的HP515临床II期试验于近日完成首批参与者入组。截至公告披露日，国内无同类靶点产品获批上市。HP515于2024年8月获得中国国家药品监督管理局批准用于代谢性脂肪性肝炎，并于2024年9月获得美国食品药品监督管理局的批准用于代谢性脂肪性肝炎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688302","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773107732651,"stockEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":-0.0829},{"period":"3month","weight":-0.2257},{"period":"6month","weight":-0.2438},{"period":"1year","weight":0.083},{"period":"ytd","weight":-0.1452}],"compareEarnings":[{"period":"1week","weight":-0.0206},{"period":"1month","weight":0.0076},{"period":"3month","weight":0.0479},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.2147},{"period":"ytd","weight":0.0322}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海创药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6815人(较上一季度增加3.97%)","perCapita":"14529股","listingDate":"2022-04-12","address":"四川省成都市武侯区高新区科园南路5号蓉药大厦1栋4层附2、3号","registeredCapital":"9901万元","survey":" 海创药业股份有限公司的主营业务是肿瘤、代谢性疾病等重大治疗领域的创新药物研发。公司的主要产品是HC-1119、HP518（PROTAC）、HP568（PROTAC）、HP537、HP560、HP501、HP515。公司荣获“2024年成都市企业技术中心”，“2024中国医药研发排行榜化药榜单前100强”，“成都市高新区“金熊猫未来星”·企业关键核心技术奖”等荣誉及称号。","listedPrice":42.92},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业,688302,海创药业股票,海创药业股票老虎,海创药业股票老虎国际,海创药业行情,海创药业股票行情,海创药业股价,海创药业股市,海创药业股票价格,海创药业股票交易,海创药业股票购买,海创药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}